Related Experiment Video

Updated: Dec 7, 2025

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.3K

Treatment of Patients With Non-small-cell Lung Cancer With Uncommon EGFR Mutations in Clinical Practice

Yutaka Yamada1, Tomohiro Tamura2, Yusuke Yamamoto3

  • 1Respiratory Center, Ibaraki Prefectural Central Hospital and Cancer Center, Kasama, Japan.

Anticancer Research
|September 29, 2020
PubMed
Abstract

Insights

Second-generation or later tyrosine kinase inhibitors (TKIs) and chemotherapy show promise for non-small cell lung cancer patients with uncommon EGFR mutations, potentially improving progression-free survival.

Area of Science:

  • Oncology
  • Medical Genetics

Background:

  • Non-small cell lung cancer (NSCLC) treatment is often guided by common EGFR mutations.
  • Uncommon EGFR mutations present unique therapeutic challenges.
  • Real-world data on outcomes for these patients are limited.

Purpose of the Study:

  • To evaluate clinical outcomes in NSCLC patients with uncommon EGFR mutations.
  • To compare the efficacy of different EGFR tyrosine kinase inhibitors (TKIs) and chemotherapy.

Main Methods:

  • Retrospective chart review across 15 medical institutions.
  • Data collected from April 2008 to March 2019.
  • Analysis of progression-free survival (PFS) and overall survival.

Main Results:

  • 102 patients with uncommon EGFR mutations were identified.
  • Afatinib and osimertinib showed significantly longer PFS compared to gefitinib or erlotinib (p=0.030).
  • Chemotherapy was effective for patients with EGFR exon 20 insertions.

Conclusions:

  • Second-generation or later TKIs (afatinib, osimertinib) may improve survival in NSCLC with uncommon EGFR mutations.
  • Cytotoxic chemotherapy is a viable option for specific mutations like exon 20 insertions.
  • These findings support personalized treatment strategies for NSCLC.
Keywords:
Clinical practiceEGFRepidermal growth factor receptornon-small cell lung canceruncommon mutation

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.1K
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.5K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.7K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.5K